ArticleEquity neuroscience2025
Use of the visual analogue Parkinson's Disease Sleep Scale in Nigeria.
Article in Equity neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Sleep disturbances are common in persons with Idiopathic Parkinson's disease (PD) but often go undetected by attending physicians. Due to its simplicity, the visual analogue PD Sleep Scale (PDSS) could be valuable in the detection and management of sleep disturbances in contexts such as Nigeria where text heavy self-report assessments are difficult to implement due to limited formal education. We aim to test the utility of the PDSS in identifying nocturnal sleep problems in Nigerians with PD. Methods: We evaluated a dataset comprising information collected in southwestern Nigeria between February 2023 and June 2024 as part of a two-centre prevalence and case control study of behavioural symptoms in clinic attendees with PD. Controls were neurologically healthy persons who were matched for age, sex, education and outpatient status. Nocturnal sleep problems were assessed using the PDSS. We also independently administered the Neuropsychiatric Inventory Questionnaire (NPI-Q). We examined indicators of construct validity by comparing the PDSS with the NPI-Q nighttime behavioural subscale, known group validity by comparing with Hoehn and Yahrs stages of PD, and discriminant validity by comparing persons with PD with or without sleep problems. We generated Spearman correlation coefficients, Games-Howell post hoc adjustments in ANOVA, and step-down Bonferroni corrections for multiple comparisons. Results: Among 150 persons with PD and 150 matched neurologically healthy controls, PDSS scores were discriminated in 13 out of the 15 items (step-down Bonferroni corrected Conclusion: The PDSS was useful in identifying a variety of nocturnal sleep problems in people living with PD. These results provide support for the utility of the tool in Nigeria and similar contexts where many patients have limited or no formal education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.